Ionis Pharmaceuticals Inc (IONS) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Summary

Ionis Pharmaceuticals Inc (Ionis) formerly ISIS Pharmaceuticals, Inc. focuses on the discovery and development of RNA-targeted drugs. The company develops first in-class medicines for the treatment of cardiovascular and metabolic disorders, cancer and rare diseases. Ionis develops its products based on its proprietary antisense technology. Its lead product candidates in Phase III development include Kynamro injection being developed in collaboration with Genzyme for the reduction of low-density lipoprotein cholesterol in patients suffering from homozygous familial hypercholesterolemia, or HoFH; Volanesorsen being developed for the treatment of rare, genetic disorders marked by severely high triglyceride levels; IONIS-TTRRx, a first-in-class drug for the treatment of all forms of TTR amyloidosis and Nusinersen being developed for the spinal muscular atrophy (SMA). Ionis is headquartered in Carlsbad, California, the US.

Ionis Pharmaceuticals Inc (IONS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.


List of Tables 5
List of Figures 5
Ionis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Ionis Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Ionis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Ionis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Ionis Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 12
Ionis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
Ionis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 16
Private Equity 16
Ionis Pharma Recommends Stockholders to Reject Mini-Tender Offer of TRC Capital 16
Partnerships 17
Biogen and Ionis Pharma Enter into Agreement 17
Biogen and Ionis Pharma Enter into Agreement 18
Novartis Enters into Option Agreement with Ionis Pharma and Akcea Therapeutics 19
Ionis Pharma Enters into Agreement with Dynacure 20
Ionis Pharma Enters into Agreement with Cystic Fibrosis Foundation 21
Ionis Pharma Partners with University of Texas MD Anderson Cancer Center 22
Biogazelle Enters into Research Agreement with Isis Pharma 23
Isis Pharma Enters into Agreement with Janssen Biotech to Discover and Develop RNA-Targeted Therapeutics 24
Biogen Idec And Isis Pharma Enter Into R&D Agreement To Develop Treatments For Neurological Disorders 25
Roche Enters Into Co-Development Agreement With Isis Pharma For Huntingtons Disease Treatment 26
AstraZeneca Expands Co-Development Agreement with Isis Pharma 27
Biogen Idec Enters Into Agreement With Isis Pharma To Develop Antisense Drugs For Neurological Disorders 28
Biogen Idec Enters Into Agreement With Isis Pharma To Develop Antisense Drug For Myotonic Dystrophy 29
Biogen Idec Enters Into Co-Development Agreement With Isis Pharma 31
Licensing Agreements 33
Akcea Therapeutics Enters into Licensing Agreement with Ionis Pharma 33
AstraZeneca Enters into Licensing Agreement with Ionis Pharma 35
Ionis Pharma Enters into License Agreement with Roche for IONIS-HTTRx 36
Janssen Biotech Enters into Licensing Agreement with Ionis Pharma 37
Ionis Pharma Enters into Licensing Agreement with Dynacure 38
Suzhou Ribo Enters into Licensing Agreement with Ionis Pharma 39
Biogen Exercises Option for Licensing Agreement with Ionis Pharma 40
Janssen Biotech Enters into Licensing Agreement with Ionis Pharma 41
Kastle Therapeutics Acquires Global Rights for KYNAMRO Injection from Ionis Pharma 42
Ionis Pharmaceuticals Enters Into Licensing Agreement with Glaxo Group and GlaxoSmithKline 43
Akcea Therapeutics Enters Into Licensing Agreement With Ionis Pharma 44
AstraZeneca Enters into Licensing Agreement with Isis Pharma 46
Bayer HealthCare Amends Licensing Agreement with Ionis Pharma 47
Xenon Pharma Exercises Option For Licensing Agreement With Isis Pharma For Antisense Drug XEN701 48
Astrazeneca Enters into Licensing Agreement with Isis Pharma 50
Equity Offering 51
Akcea Therapeutics Raises USD143.8 Million in IPO 51
Akcea Therapeutics Raises USD50 Million in Private Placement of Shares 53
Ionis Pharma Files Registration Statement for Public Offering of Shares for up to USD68.7 Million 54
Akcea Therapeutics Raises USD100 Million in Private Placement of Series A Preferred Stock 55
Isis Pharma Completes Public Offering Of Shares For US$182.7 Million 56
Debt Offering 58
Isis Pharma Completes Private Placement of Notes for USD500 Million 58
Isis Pharma Completes Private Placement Of Convertible Senior Notes Due 2019 For US$201 Million 60
Ionis Pharmaceuticals Inc - Key Competitors 61
Ionis Pharmaceuticals Inc - Key Employees 62
Ionis Pharmaceuticals Inc - Locations And Subsidiaries 63
Head Office 63
Other Locations & Subsidiaries 63
Joint Venture 64
Recent Developments 65
Financial Announcements 65
May 04, 2018: Ionis Announces First Quarter 2018 Financial Results 65
Feb 27, 2018: Ionis Announces Fourth Quarter and Full Year 2017 Financial Results 68
Nov 07, 2017: Ionis Pharmaceuticals Reports Financial Results and Highlights for Third Quarter 2017 71
Aug 08, 2017: Ionis Provides Improved 2017 Guidance Following Strong Financial Performance 73
May 09, 2017: Ionis Reports Financial Results and Highlights for First Quarter 2017 75
Feb 28, 2017: Ionis 2016 Financial Results Outperform Financial Guidance 77
Jan 06, 2017: Ionis Pharmaceuticals Significantly Improves Upon 2016 Financial Guidance 81
Corporate Communications 82
Jun 18, 2018: Ionis Pharmaceuticals Names Damien McDevitt As Chief Business Officer 82
Nov 07, 2017: Ionis Announces Management Transitions 83
Other Significant Developments 84
Jun 12, 2018: Akcea and Ambry Genetics to Launch hATTR Compass, a Genetic Testing Program for People with Suspected Hereditary ATTR Amyloidosis 84
Appendix 85
Methodology 85
About GlobalData 85
Contact Us 85
Disclaimer 85

List Of Tables

List of Tables
Ionis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Ionis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Ionis Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Ionis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Ionis Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 10
Ionis Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 12
Ionis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
Ionis Pharma Recommends Stockholders to Reject Mini-Tender Offer of TRC Capital 16
Biogen and Ionis Pharma Enter into Agreement 17
Biogen and Ionis Pharma Enter into Agreement 18
Novartis Enters into Option Agreement with Ionis Pharma and Akcea Therapeutics 19
Ionis Pharma Enters into Agreement with Dynacure 20
Ionis Pharma Enters into Agreement with Cystic Fibrosis Foundation 21
Ionis Pharma Partners with University of Texas MD Anderson Cancer Center 22
Biogazelle Enters into Research Agreement with Isis Pharma 23
Isis Pharma Enters into Agreement with Janssen Biotech to Discover and Develop RNA-Targeted Therapeutics 24
Biogen Idec And Isis Pharma Enter Into R&D Agreement To Develop Treatments For Neurological Disorders 25
Roche Enters Into Co-Development Agreement With Isis Pharma For Huntingtons Disease Treatment 26
AstraZeneca Expands Co-Development Agreement with Isis Pharma 27
Biogen Idec Enters Into Agreement With Isis Pharma To Develop Antisense Drugs For Neurological Disorders 28
Biogen Idec Enters Into Agreement With Isis Pharma To Develop Antisense Drug For Myotonic Dystrophy 29
Biogen Idec Enters Into Co-Development Agreement With Isis Pharma 31
Akcea Therapeutics Enters into Licensing Agreement with Ionis Pharma 33
AstraZeneca Enters into Licensing Agreement with Ionis Pharma 35
Ionis Pharma Enters into License Agreement with Roche for IONIS-HTTRx 36
Janssen Biotech Enters into Licensing Agreement with Ionis Pharma 37
Ionis Pharma Enters into Licensing Agreement with Dynacure 38
Suzhou Ribo Enters into Licensing Agreement with Ionis Pharma 39
Biogen Exercises Option for Licensing Agreement with Ionis Pharma 40
Janssen Biotech Enters into Licensing Agreement with Ionis Pharma 41
Kastle Therapeutics Acquires Global Rights for KYNAMRO Injection from Ionis Pharma 42
Ionis Pharmaceuticals Enters Into Licensing Agreement with Glaxo Group and GlaxoSmithKline 43
Akcea Therapeutics Enters Into Licensing Agreement With Ionis Pharma 44
AstraZeneca Enters into Licensing Agreement with Isis Pharma 46
Bayer HealthCare Amends Licensing Agreement with Ionis Pharma 47
Xenon Pharma Exercises Option For Licensing Agreement With Isis Pharma For Antisense Drug XEN701 48
Astrazeneca Enters into Licensing Agreement with Isis Pharma 50
Akcea Therapeutics Raises USD143.8 Million in IPO 51
Akcea Therapeutics Raises USD50 Million in Private Placement of Shares 53
Ionis Pharma Files Registration Statement for Public Offering of Shares for up to USD68.7 Million 54
Akcea Therapeutics Raises USD100 Million in Private Placement of Series A Preferred Stock 55
Isis Pharma Completes Public Offering Of Shares For US$182.7 Million 56
Isis Pharma Completes Private Placement of Notes for USD500 Million 58
Isis Pharma Completes Private Placement Of Convertible Senior Notes Due 2019 For US$201 Million 60
Ionis Pharmaceuticals Inc, Key Competitors 61
Ionis Pharmaceuticals Inc, Key Employees 62
Ionis Pharmaceuticals Inc, Subsidiaries 63
Ionis Pharmaceuticals Inc, Joint Venture 64

List Of Figures

List of Figures
Ionis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Ionis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Ionis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Ionis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Ionis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Ionis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8
Ionis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Ionis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Ionis Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 12

2018 Pharmaceutical Competitive Intelligence: Ionis Pharmaceuticals Performance, Capabilities, Goals and Strategies

This report is part of the Competitive Analysis Series, which includes current assessments of more than 1,000 companies worldwide. The assessments include all or some of the following: Organization and

USD 950 View Report

Ionis Pharmaceuticals: Performance, Capabilities, Goals and Strategies in the Global Pharmaceutical Market

This report is part of the Competitive Analysis Series prepared by LeadingMarketResearch.com to help current suppliers and potential market entrants realistically assess their financial, technological and marketing capabilities in relation

USD 950 View Report

EyePoint Pharmaceuticals Inc (PSDV) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

EyePoint Pharmaceuticals Inc (EyePoint), formerly pSivida Corp, is a biopharmaceutical company that provides development of miniaturized, sustained-release drug delivery products and technologies. The company offers products such as iluvien, retisert

USD 250 View Report

EyePoint Pharmaceuticals Inc (PSDV) - Medical Equipment - Deals and Alliances Profile

EyePoint Pharmaceuticals Inc (EyePoint), formerly pSivida Corp, is a biopharmaceutical company that provides development of miniaturized, sustained-release drug delivery products and technologies. The company offers products such as iluvien, retisert

USD 250 View Report

Your are not allow to send sample request

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available